Program
Actinium-225
Also written as “[225Ac]Ac-FL-261”, “[225Ac]Ac-AKY-2519 (therapeutic)” and “Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265])”.
Its studies are mostly in Prostatic Neoplasms · Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Carcinoma, Renal Cell · Triple Negative Breast Neoplasms, led by 6 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Aktis Oncology | 33 open or running | phase 1since May 28, 2025 | May 28, 2025 | Dec 2027phase 1 · NCT07581184 |
| Alpha-9 Oncology USA | 21 open or running | phase 1since Jun 27, 2025 | Jun 27, 2025 | Dec 2028phase 1 · NCT07661641 |
| AstraZeneca | 21 open or running | phase 3since Apr 22, 2026 | Nov 9, 2018 | Jun 4, 2029phase 3 · NCT07611110 |
| Eli Lilly | 11 open or running | phase 1since Jan 3, 2024 | Jan 3, 2024 | Sep 2027phase 1 · NCT06229366 |
| Full-Life Technologies UK | 11 open or running | phase 2since Sep 23, 2026 | Sep 23, 2026 | Jun 30, 2030phase 2 · NCT07873450 |
| PeptiDream | 11 open or running | phase 1since Jun 17, 2026 | Jun 17, 2026 | May 2029phase 1 · NCT07688187 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 9, 2018First study: phase 1 study in Endometrial NeoplasmsNew to AstraZenecaAstraZeneca · NCT03746431 · 78 enrolled · United States, Australia, Canada
- Jan 3, 2024Eli Lilly's first study: phase 1 study in Prostatic NeoplasmsNew to Eli LillyEli Lilly · NCT06229366 · 142 enrolled · Canada
- May 28, 2025Aktis Oncology's first study: phase 1 study in Triple Negative Breast NeoplasmsNew to Aktis OncologyAktis Oncology · NCT07020117 · 150 planned · United States
- Jun 27, 2025Alpha-9 Oncology USA's first study: phase 1 study in Uveal MelanomaNew to Alpha-9 Oncology USAAlpha-9 Oncology USA · NCT07076550 · 5 enrolled · Australia
- Apr 22, 2026Phase 3 study in Prostatic NeoplasmsPhase 3 reachedAstraZeneca · NCT07611110 · 670 planned · United States, Australia, Austria and more
- May 6, 2026Phase 1 study in Prostatic NeoplasmsAktis Oncology · NCT07581184 · 138 planned · United States
- Jun 9, 2026Phase 1 study in Breast NeoplasmsAlpha-9 Oncology USA · NCT07661641 · 115 planned · Australia
- Jun 17, 2026PeptiDream's first study: phase 1 study in Carcinoma, Renal CellNew to PeptiDreamPeptiDream · NCT07688187 · 60 planned · United States
- Sep 23, 2026Full-Life Technologies UK's first study: phase 2 study in Colorectal NeoplasmsNew to Full-Life Technologies UKFull-Life Technologies UK · NCT07873450 · 208 planned · United States, Australia, China
- Oct 15, 2026Phase 1 study in Carcinoma, Non-Small-Cell LungAktis Oncology · NCT07887971 · 152 planned · United States
Ahead
- Sep 2027Primary completion: phase 1 study in Prostatic NeoplasmsEli Lilly · NCT06229366
- Dec 2027Primary completion: phase 1 study in Prostatic NeoplasmsAktis Oncology · NCT07581184
- Dec 2027Primary completion: phase 1 study in Triple Negative Breast NeoplasmsAktis Oncology · NCT07020117
- Dec 2028Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungAktis Oncology · NCT07887971
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07887971Carcinoma, Non-Small-Cell Lung · United States | 1 | Recruiting | Aktis Oncology | Dec 2028 | 152 |
| NCT07873450Colorectal Neoplasms · United States, Australia, China | 2 | Recruiting | Full-Life Technologies UK | Jun 30, 2030 | 208 |
| NCT07688187Carcinoma, Renal Cell · United States | 1 | Recruiting | PeptiDream | May 2029 | 60 |
| NCT07661641Breast Neoplasms · Australia | 1 | Recruiting | Alpha-9 Oncology USA | Dec 2028 | 115 |
| NCT07581184Prostatic Neoplasms · United States | 1 | Recruiting | Aktis Oncology | Dec 2027 | 138 |
| NCT07611110Prostatic Neoplasms · United States, Australia, Austria and more | 3 | Recruiting | AstraZeneca | Jun 4, 2029 | 670 |
| NCT07076550Uveal Melanoma · Australia | 1 | Terminated | Alpha-9 Oncology USA | Jul 9, 2026 | 5 |
| NCT07020117Triple Negative Breast Neoplasms · United States | 1 | Recruiting | Aktis Oncology | Dec 2027 | 150 |
| NCT06229366Prostatic Neoplasms · Canada | 1 | Active, not recruiting | Eli Lilly | Sep 2027 | 142 |
| NCT03746431Endometrial Neoplasms · United States, Australia, Canada | 1 | Terminated | AstraZeneca | Dec 3, 2025 | 78 |
How it is read
Names in the registry
- “[225Ac]Ac-FL-261”, 3 entries
- “[225Ac]Ac-AKY-2519 (therapeutic)”, 2 entries
- “Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265])”, 1 entry
- “[Ac-225]-PSMA-62 (mCRPC)”, 1 entry
- “[Ac-225]-PSMA-62 (OmHSPC)”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 3 studies
- Colorectal Neoplasms, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
- Carcinoma, Renal Cell, 1 study
- Triple Negative Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.